SmartPharm focuses on technologies with reduced regulatory risk of barriers to clinical implementation
SmartPharm avoids approaches that have already demonstrated challenges in gaining regulatory approval (FDA, Health Canada and China FDA). We therefore avoid:
- Use of viral vectors or other approaches requiring pharmaceutical-based immune suppression.
- The use of electroporation as a delivery technology.
- Non-viral delivery technologies that face key regulatory hurdles.
- Expensive or highly complex manufacturing processes.
SmartPharm implements an accelerated development ecosystem
SmartPharm utilizes an established network of best-in-class development partners to speed development of new therapeutics into clinical testing. We tap networks and approaches that have already proved to be able to move new candidates into clinical testing faster and less expensively than industry standards.